RecruitingPhase 2NCT06647550
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Sponsor
Hyundai Pharm
Enrollment
160 participants
Start Date
Dec 12, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Eligibility
Min Age: 19 YearsMax Age: 75 Years
Inclusion Criteria1
- Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening.
Exclusion Criteria3
- Type 1 diabetes or another immune-mediated diabetes syndrome
- BMI: \> 40 kg/m2
- C-peptide: \< 0.5ng/mL
Interventions
DRUGHD-6277 100mg
PO, QD
DRUGHD-6277 50mg
PO, QD
DRUGHD-6277 25mg
PO, QD
DRUGPlacebo
PO, QD
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06647550
Related Trials
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
NCT069066276 locations
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
NCT069066406 locations
Investigation of Motor Imagery Ability, Body Awareness and Cognitive Functions in Type 2 Diabetes Mellitus
NCT065888941 location
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
NCT074652241 location